ERBB2 and gastric cancer: In particular, the Trastuzumab (T-mab) for Gastric Cancer (ToGA) trial demonstrated the clinical efficacy of additional T-mab as a first-line regimen in patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable advanced gastric cancer [4].